Will ADM executives conduct additional discretionary stock sales exceeding $5M in aggregate by Q3 2026?

The Q1 2026 selling pattern ($10M+ from 4 executives in a 30-day window) established a clear precedent. Restricted stock grants vest on predictable schedules, meaning additional vesting events will occur in H1-H2 2026. The same executives who sold in Q1 likely have additional tranches vesting. Given that all four chose to sell rather than hold, the default assumption should be they will repeat the behavior with future vestings. The $5M threshold is relatively modest compared to Q1's $10M+.

The resolution excludes 10b5-1 pre-planned sales and tax withholding dispositions, focusing on discretionary selling. This narrows the scope somewhat. However, the Q1 selling was specifically discretionary open market sales from vested restricted stock. If the same executives have additional tranches vesting (which is typical for annual grant programs), the pattern suggests they will sell again. The uncertain commodity cycle and class action overhang reduce incentive to hold. Counter-argument: SEC compliance teams may discourage clustered selling given the governance optics.

The question covers a 6-month window (April-September 2026). With 4 executives having already demonstrated willingness to sell discretionary shares, and typical annual compensation structures creating multiple vesting dates per year, there will likely be opportunities. However, the insider window restrictions around earnings (blackout periods) limit when executives can sell. With 4 quarterly blackout periods of ~6 weeks each in a 6-month window, available trading days are reduced. Still, the precedent and incentives lean toward YES.

The base rate for executive selling at companies with regular equity compensation programs is high. ADM has at least 4 executives with demonstrated willingness to sell discretionary shares. Annual equity compensation typically vests on anniversary dates, creating 2-3 vesting events per executive per year. Even if only 2 of the 4 sell in the next window, at $2-3M per executive, the $5M aggregate threshold is easily met. The combination of trough earnings, class action uncertainty, and recovery narrative they may not believe creates strong selling incentive.

The Q1 selling was notable for its clustering, but the resolution doesn't require clustering — just aggregate exceeding $5M. Individual executives selling at different times across a 6-month window is the more likely pattern. The key risk to YES is if ADM's general counsel restricts discretionary selling given governance sensitivity post-SEC settlement. Companies under active litigation sometimes implement stricter trading policies. But this would be unusual for a company that has already settled with the SEC.

This is genuinely close to 50/50. The precedent from Q1 favors YES, but the governance optics of continued selling while under class action scrutiny may cause executives to hold. The $5M threshold is modest but the discretionary-only criterion excludes the most predictable forms of selling. There's real uncertainty here about executive behavior — the analysis classified governance as MIXED precisely because the selling pattern is ambiguous.

Strong precedent from Q1 2026 selling pattern. Multiple executives have shown willingness to sell. Annual vesting schedules create opportunities. $5M threshold is modest. Lean toward YES.

The precedent favors selling, but governance concerns and litigation sensitivity may restrain. Around 50-55% reflects the balance between demonstrated behavior and potential restraint.

The combination of precedent, vesting schedules, and modest threshold makes additional selling more likely than not. But not by a large margin given governance constraints. 55% is appropriate.